Non-invasive neuromodulation

Non-invasive neuromodulation covers the techniques that change nervous-system activity from outside the body: magnetic pulses that induce currents in cortex, weak direct or alternating currents applied to the scalp, focused ultrasound aimed through the skull, and electrical stimulation of peripheral nerves reachable at the skin. These methods avoid the surgery, cost, and hardware dependence of Deep brain stimulation and of the implanted devices grouped under Neuroprosthetics, whose stimulation can be adjusted or switched off but whose electrodes come out only with another operation. The price is far less spatial precision and shallower reach, and several of the most popular methods rest on an evidence base that has not survived rigorous replication.

§Modalities

Transcranial magnetic stimulation (TMS) discharges a capacitor through a coil held against the scalp, producing a rapidly changing magnetic field that induces an electric field in the underlying cortex strong enough to depolarize axons. A single pulse over motor cortex produces a measurable twitch. That gives TMS something no other non-invasive method has: a direct, objective readout that the stimulation reached its target, a form of ground truth that recording-based systems such as a Brain–computer interface have to establish statistically. The therapeutic form is repetitive TMS delivered in trains over days, and patterned protocols such as intermittent theta burst compress a session from forty minutes to a few.

Transcranial electrical stimulation passes 1-2 mA between scalp electrodes. Direct current (tDCS) shifts resting membrane potentials, making neurons under the anode marginally more likely to fire and those under the cathode marginally less; it does not itself trigger action potentials. Alternating current (tACS) aims to entrain endogenous oscillations at a chosen frequency. Both are cheap, portable, and easy to build, which accounts for their popularity in research and for their regulatory problems.

Transcranial focused ultrasound (tFUS) at low intensity modulates neural activity, most likely through mechanical effects on ion channels and membranes rather than heating. What sets it apart is depth with focus: an ultrasound beam can be steered to a target a few millimetres across in the thalamus or amygdala, structures that magnetic or electrical scalp stimulation cannot reach. The first human sensory-cortex demonstrations date from the 2010s.¹ High-intensity focused ultrasound is a different technology. Under magnetic resonance guidance it ablates the thalamic tremor target, and it is approved for essential tremor.

Peripheral approaches stimulate nerves that project into the brain. Vagus nerve stimulation is long established in implanted form for epilepsy and treatment-resistant depression. Transcutaneous variants stimulate the auricular branch at the ear or the cervical vagus at the neck, and are cleared for headache indications.

§How they act on tissue

The physics sets the limits. The skull is a poor conductor and a strong acoustic barrier, and the scalp is a low-resistance shunt. Direct measurements in human cadaver preparations found that the great majority of current applied at conventional tDCS intensities is shunted through the scalp, leaving field strengths in cortex of roughly a quarter of a volt per metre. That is well below the threshold for driving spikes, and at the low end of what modulates firing probability in animal recordings.² The finding did not show that tDCS does nothing. It showed that whatever tDCS does must be a subtle modulation of ongoing activity, and it offered an explanation for both the small effect sizes and the high inter-individual variability the literature reports.

Spatial focality is worse than most figures suggest. A conventional two-electrode tDCS montage spreads current across large regions of cortex. TMS achieves perhaps a centimetre of focality at the gyral crown and cannot reach the depths where the targets of implanted therapy sit. Ultrasound is the exception, and its focality explains why interest has moved toward it.

Individual variability is the other structural problem. Skull thickness, cortical folding, baseline neurotransmitter state, and prior activity all change the response, and studies of standard plasticity protocols find that a substantial fraction of healthy participants show no effect or the opposite of the expected one. Group averages are therefore a poor guide to how any one person will respond.

§Clinical evidence

Repetitive TMS for major depression is the best-supported application. It was cleared in the United States in 2008 after a sham-controlled trial and is reimbursed in many health systems. In medication-resistant patients it produces response rates that are clinically meaningful, though they do not approach the remission rates of electroconvulsive therapy. An accelerated protocol, which delivers many theta-burst sessions over five days with individualized functional-connectivity targeting, reported high remission rates in a small randomised sham-controlled trial and was cleared in 2022; replication at scale is still in progress.³ TMS is also cleared for obsessive-compulsive disorder and as an aid to smoking cessation.

Transcranial electrical stimulation has no approved US indication. European expert guidelines assign tDCS probable efficacy for depression and for some pain conditions, and find insufficient evidence for most other proposed uses.⁴ A tDCS headset is regulated as a medical device for depression in some European jurisdictions. The clinical case is real but modest, and weaker than the volume of published literature implies.

Vagus nerve stimulation for treatment-resistant depression has been studied for two decades with persistently ambiguous results, and a large sham-controlled trial reported mixed outcomes in the mid-2020s. Non-invasive ear stimulation has a much thinner evidence base than its commercial presence suggests.

§Cognitive enhancement and the replication problem

The largest gap between claim and evidence concerns tDCS as a cognitive enhancer in healthy people. Hundreds of studies report improvements in working memory, attention, learning rate, and motor skill acquisition, typically with fewer than twenty participants per group, one session, and one outcome measure among several collected. A meta-analysis pooling single-session tDCS studies in healthy adults found no reliable effect on any cognitive measure once the whole literature was considered.⁵ That analysis was itself contested on methodological grounds and the argument has not fully resolved. Still, the field's own subsequent work has moved toward larger samples, preregistration, and individualized dosing because the earlier literature did not hold up.

The structural causes are familiar: small samples, flexible analysis, publication bias toward positive results, and sham conditions that participants can often detect from the scalp sensation. Detectable shams are not peculiar to stimulation. They are the central objection to trials of Psychedelic therapy, where an active dose is unmistakable within the hour. A tingle under an electrode is a far weaker cue, so the blind in stimulation trials is degraded rather than absent. A further complication is that tDCS effects are frequently state-dependent, helping poor performers and impairing good ones, so a group average can be near zero while real effects exist in subgroups. That calls for careful design, but it does not defend the existing literature.

The same caution applies to claims made for Nootropics and to any proposal that Intelligence amplification can be achieved by stimulating cortex. Nothing in the current evidence supports durable, general cognitive gain in healthy adults from any non-invasive stimulation method. The implanted approach to the same goal, the hippocampal Memory prosthesis, has only within-session results in patients. Claims that stimulation can reduce sleep need, discussed under Engineered sleep reduction, rest on still weaker foundations.

What a positive result usually means

A typical enhancement finding is a within-session improvement of a few percent on one task, in around twenty people, relative to a sham the participants may have identified. It is not evidence that a device makes anyone smarter, and it does not transfer to untrained tasks.

§The consumer market and its regulation

Direct-to-consumer stimulation devices occupy a regulatory gap. Because they are marketed for relaxation, sleep, focus, or athletic training rather than for treating disease, many are sold under general-wellness provisions that do not require efficacy evidence. A sports-oriented tDCS headset attracted significant attention in the 2010s before its maker ceased operations. Cranial electrotherapy devices continue to be sold for anxiety and insomnia, and an active do-it-yourself community builds its own units, an activity that sits alongside the practices described under Biohacking and grinders.

Consumer electroencephalography headsets are increasingly sold alongside these devices, and scalp recordings support more inference than their crudeness suggests. That concern is taken up under Mental privacy, and the legislation addressing it under Neurorights.

Harms are mostly minor: skin irritation and burns under electrodes, headache, and transient mood change. TMS is the notable exception, since seizure is a rare but documented risk that keeps it in clinical settings. The more consequential problem is opportunity cost and misinformation, with devices sold on the strength of a literature that has not replicated. Military interest in stimulation for sustained vigilance has produced similar claims with similar evidentiary weakness. Whether such devices belong in competitive settings is unresolved, as discussed under Enhancement in sport and Bioethics of enhancement.

§Outlook

Focused ultrasound is the modality most likely to change what non-invasive stimulation can do, because it is the only one that combines depth with a focal spot. If low-intensity ultrasound can reliably modulate specific deep nuclei in humans, it would offer a reversible, repeatable alternative to implanted electrodes for some psychiatric and pain indications. It would also let investigators run causal experiments in deep human structures that currently require surgery. As of 2026 the human evidence consists of small studies with heterogeneous protocols, and the dose-response relationship is not well characterized.

A separate line of animal work aims stimulation at the brain's fluid clearance rather than at a symptom. In October 2026 a group in Beijing reported that a single ten-minute exposure to 40.68 MHz ultrashort-wave radio-frequency energy, a physiotherapy modality, raised delta-band power and sped glymphatic tracer clearance in mice. A week of daily sessions lowered amyloid staining and improved memory tasks in an Alzheimer's mouse model.⁶ The work is a single cohort of mice with no human data, and the clearance mechanism it targets is itself disputed.

The second trend is closing the loop. Stimulation timed to a measured brain state (an oscillation phase, a sleep spindle, a decoded attentional lapse) should outperform stimulation delivered on a fixed schedule, and it borrows directly from the methods of Neural decoding and from the adaptive control now used in implanted devices. Whether that gain materializes in practice will determine if non-invasive methods remain a weaker substitute for implanted devices or become a distinct clinical tool with their own indications. The techniques that achieve genuine cell-type specificity, Optogenetics above all, work in animal brains and have reached people only in the eye. A brain target would need gene delivery to a defined population and a light source implanted next to it, which leaves ultrasound as the only non-invasive candidate combining depth with focus.

§See also

• Deep brain stimulation
• Brain–computer interface
• Neuroprosthetics
• Nootropics
• Intelligence amplification
• Human enhancement
• Biohacking and grinders
• Mental privacy

§References